CClinicalTrials.gg
RecruitingNCT03747146EKAT-TeleTPSUpdated Apr 28, 2026

Enhanced Recovery After Surgery (ERAS) Total Knee Replacement (TKR) With a Transitional Pain Service

An interventional study of Continuous Adductor Canal Catheter (ACC) and Adductor Canal block with sham catheter in Anesthesia, sponsored by Hospital for Special Surgery, New York. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-28.

Sponsored by Hospital for Special Surgery, New York · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2018; still recruiting 7 years 10 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
94
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

A comparison of two anesthetic techniques for total knee replacements: (1) Peri-Articular Injection (PAI), local infiltration between the popliteal artery and capsule of the knee block (IPACK) and single-shot adductor canal block (ACB) vs. (2) PAI, IPACK and continuous adductor canal block catheter (ACC).

Read the detailed description

Patients will be randomized to one of two groups: one group will receive a PAI, IPACK and single-shot adductor canal block; one group will receive PAI, IPACK and continuous adductor canal block catheter.

02

Conditions studied

  • Anesthesia
03

In context

Lead sponsor

Hospital for Special Surgery, New York is the lead sponsor of 217 studies on the registry; 39 are open to participants now.

Of its 27 completed or terminated interventional studies of FDA-regulated products, 20 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Patients with osteoarthritis scheduled for a primary total knee arthroplasty with a participating surgeon
  • Planned use of regional anesthesia
  • Ability to follow study protocol
  • English speaking (secondary outcomes include questionnaires validated in English only)
  • Lives within one hour of the hospital
  • Has a smart phone

Exclusion criteria

Exclusion Criteria:

  • Hepatic or renal insufficiency
  • Younger than 18 years old or older than 65 years ol
  • Patients undergoing general anesthesia
  • Allergy or intolerance to one of the study medications
  • BMI >40
  • Diabetes
  • American Society of Anesthesiologists (ASA) status III or IV
  • Chronic gabapentin/pregabalin use (regular use for longer than 3 months)
  • Patients with chronic pain (from a referral to chronic pain service) or a pain catastrophizing scale (PCS >30)
  • Patients with severe valgus deformity or flexion contracture
  • Patients unable to follow home catheter instructions and unwilling to go home with an infusing catheter
  • Patients who have no home caregivers in the event that a catheter is to be sent home with the patient
  • Patients with planned stay at rehab facility (to avoid medical device being tampered with at the rehab facility)
  • Non-English speakers (secondary outcomes include questionnaires validated in English only)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
94 participants (estimated)

Study arms

  • Active comparator
    Continuous Adductor Canal Catheter (ACC)

    Patients will receive a combined spinal epidural, PAI, IPACK, and a continuous adductor canal catheter

    Device: Continuous Adductor Canal Catheter (ACC)

  • Sham comparator
    Adductor Canal block with sham catheter

    Patients will receive a combined spinal epidural, PAI, IPACK, and an adductor canal block. The patient will also receive a sham catheter.

    Device: Adductor Canal block with sham catheter

Interventions

  • DeviceContinuous Adductor Canal Catheter (ACC)

    At the end of the case or in the PACU, a pseudo sham catheter will be affixed mid-thigh to the skin using dermabond, steri-strips, and a chg tegaderm dressing. The catheter will be connected to the disposable pump filled with sterile saline (400 cc) and the flow rate will be set to 0. The pump will be enclosed in a carrier bag provided by the company. To ensure blinding, the carrier bag will be taped to prevent the patient from accessing it.

  • DeviceAdductor Canal block with sham catheter

    Adductor canal block (ACB) will be administered. At the end of the case or in the PACU, a catheter will be inserted and affixed mid-thigh to the skin using dermabond, steri-strips, and a chg tegaderm dressing. The catheter will be connected to the disposable pump filled with sterile saline (400 cc) and the flow rate will be set to 0. The pump will be enclosed in a carrier bag provided by the company. To ensure blinding, the carrier bag will be taped to prevent the patient from accessing it.

06

What researchers measure

Primary outcomes

  1. Opioid consumption during 24-48 hour period

    Patients will be asked to report their opioid consumption during the 24-48 hour time period after spinal induction. This data will be converted to morphine milligram equivalents (mme).

    Time frame: Post-operative day 1-2 (24-48 hours post spinal induction)

Secondary outcomes

  1. Opioid consumption during post-anesthesia care unit (PACU) stay

    Patients will be asked to report their opioid consumption during their stay in the post-anesthesia care unit. This data will be converted to morphine milligram equivalents (mme).

    Time frame: Day of surgery from PACU arrival until transfer to in-patient floor (up to 48 hours)

07

Study locations

1 of 1 sites recruiting
  • Hospital for Special Surgery
    New York, New York 10023, United States
    • David Kim, MD · Principal investigator
    Recruiting
08

References and documents

Publications

  • Kim DH, Beathe J, Wetmore DS, Goytizolo E, Haskins SC, Swamidoss C, Reichel JF, Reisenger L, Rao P, Memtsoudis SG, Liu J. Single-injection adductor canal block with perineural dexamethasone versus continuous adductor canal catheter for total knee arthroplasty: a randomized controlled trial. Reg Anesth Pain Med. 2026 Jun 4:rapm-2026-107719. doi: 10.1136/rapm-2026-107719. Online ahead of print. PubMed 42242837 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03747146
Lead sponsor
Hospital for Special Surgery, New York
Responsible party
Sponsor
First posted
Nov 20, 2018
Start date
Nov 16, 2018
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Apr 28, 2026

Study contacts

George Birch, BS
Contact
birchg@hss.edu
212-774-7377
David Kim, MD
principal investigator · Hospital for Special Surgery, New York

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion